NCT05320120View on ClinicalTrials.gov

Investigation of Intranasal Ketamine Related Changes in Attentional Brain Networks With Functional and Structural MRI

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

June 21, 2023

Study Completion Date

June 21, 2023

Conditions
Ketamine Treatment
Interventions
DRUG

56mg esketamine (2x Spravato® 28 mg nasal spray)

56mg esketamine (2x Spravato® 28 mg nasal spray)

DRUG

0.9% saline solution nasal spray

0.9% saline solution nasal spray

Trial Locations (1)

1090

Department of Psychiatry and Psychotherapy, Vienna

All Listed Sponsors
lead

Rupert Lanzenberger

OTHER